Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MeMed
The company will use the money to fund its US commercialization strategy and continue to develop its host response-based product pipeline.
Minute Insight: MeMed Announces Viral/Bacterial Infection Differentiation Results, Commercial Partnership
DiaSorin will distribute MeMed BV, a rapid point-of-care test that can differentiate bacterial and viral infections, under a new commercial agreement.
Following a busy year for point of care diagnostics, the industry is facing a period of consolidation. The drive for new technologies is being countered by regulatory and financial issues.
Approved in Europe and just given the US green light, MeMed is making waves in the fight against antimicrobial resistance using advanced "host response" technology. Its CEO talks to In Vivo about strategy, commercialization and earning the right to fantasize.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
- Drug Discovery Tools